Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OneMedNet (ONMD) Research & Development (2022 - 2025)

OneMedNet (ONMD) has disclosed Research & Development for 4 consecutive years, with $443000.0 as the latest value for Q4 2025.

  • Quarterly Research & Development rose 30.29% to $443000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 2.05% year-over-year, with the annual reading at $1.5 million for FY2025, 3.27% up from the prior year.
  • Research & Development for Q4 2025 was $443000.0 at OneMedNet, up from $323000.0 in the prior quarter.
  • The five-year high for Research & Development was $880638.0 in Q4 2022, with the low at $298000.0 in Q3 2024.
  • Average Research & Development over 4 years is $454433.7, with a median of $405000.0 recorded in 2023.
  • The sharpest move saw Research & Development plummeted 43.34% in 2023, then surged 30.29% in 2025.
  • Over 4 years, Research & Development stood at $880638.0 in 2022, then tumbled by 43.34% to $499000.0 in 2023, then plummeted by 31.86% to $340000.0 in 2024, then soared by 30.29% to $443000.0 in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $443000.0, $323000.0, and $382000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.